7月2日，艾德生物今日收盘21.28元，下跌1.48%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到29.64倍，总市值83.32亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.29倍，行业中值37.02倍，艾德生物排 名第67位。 资金流向方面，7月2日，艾德生物主力资金净流出1187.10万元，近5日总体呈流出状态，5日共流出 1956.56万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13艾德生物29.6432.694.3483.32亿行业平均 51.2949.024.57106.75亿行业中值37.0237.322.4950.63亿1九安医疗10.2410.360.81172.88亿2英科医疗 10.3411.150.92163.38亿3新华医疗14.3913.331.1792.22亿4奥美医疗15.2314.931.5755.03亿5山东药玻 15.4315.481.77145.93亿6振德医疗15.5514.660.9956.46亿7康德莱15.6915.701.3033.81亿8维力医疗 16.3917.031.9237.37亿9奥泰生物16. ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)66艾德生物29.7932.864.3683.75亿行业平均 50.6449.074.68109.10亿行业中值37.0537.632.5050.67亿1天益医疗-1817.92-3113.901.9423.17亿2澳华内 镜-726.69364.475.8276.58亿3诺唯赞-431.93-510.862.3792.43亿4爱朋医疗-431.66327.945.2035.42亿5博晖 创新-337.40535.413.6049.50亿6硕世生物-147.79-2159.571.3243.23亿7奥精医疗-142.33-208.621.8826.42亿 8睿昂基因-105.65-86.741.5013.67亿9康泰医学-87.85-74.223.1357.82亿10中红医疗-74.13-59.130.9451.52亿 11热景生物-67.89-78.225.01149.40亿 来源：金融界 厦门艾德生物医药科技股份有限公司的主营业务是肿瘤基因检测试剂、软件及配套仪器，并提供检测服 务及药物临床研究服务。公司的主要产品是检测试剂、检测服务、药物临床研究服务 ...

2024 年度权益分派实施的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 2024年度权益分派方案已获2025年5月14日召开的2024年度股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司2024年度股东大会审议通过的2024年度权益分配方案如下：以未来 实施2024年度权益分配方案时股权登记日的总股本（扣除回购专用证券账户股份） 为基数，向全体股东每10股派发现金红利3元（含税），不送红股，不以资本公 积金转增股本。 若在本权益分配方案实施前公司总股本发生变动，公司将按照分配比例不变 的原则调整分配总额。 证券代码：300685 证券简称：艾德生物 公告编号：2025-036 厦门艾德生物医药科技股份有限公司 2、自2024年度权益分配方案披露至实施期间，公司在中国证券登记结算有 限责任公司深圳分公司完成了1,525,825股限制性股票的回购注销手续，公司总股 本由393,061,969股变更为391,536,144股。 3、本次实施的权 ...

厦门艾德生物医药科技股份有限公司 关于公司收到医疗器械变更注册文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、情况概述 厦门艾德生物医药科技股份有限公司（以下简称"公司"）于近日收到由国 家药品监督管理局颁发的《医疗器械变更注册文件》，公司已完成"人类10基因 突变联合检测试剂盒（可逆末端终止测序法）"产品原注册证相关事项的变更， 证券代码：300685 证券简称：艾德生物 公告编号：2025-035 具体情况如下： | 产品名称 | 注册分类 | 注册证编号 | | | 变更的主要内容 | | --- | --- | --- | --- | --- | --- | | 人类10基因突变联 | III类 | 国 械 | 注 | 准 | 预期用途增加"本试剂盒可用于定性检 | | 合检测试剂盒（可 | | 20183400507 | | | 测非小细胞肺癌（NSCLC）患者血浆样 | | 逆 末 端终 止测 序 | | | | | 本中EGFR 20号外显子插入突变（EGFR | | 法） | | | | | ex20ins），用于埃万妥单抗注射 ...

Core Viewpoint - Xiamen Adebiotech Co., Ltd. announced the repurchase and cancellation of restricted stocks involving 379 individuals, totaling 1,525,825 shares, which represents a reduction in the company's total share capital [1][5]. Summary by Sections Repurchase Details - The repurchase price for the restricted stocks is set at 11.62 CNY per share for the newly appointed supervisor, while for others, it includes the bank's current deposit interest [1][5]. - The total amount for this repurchase is 18,109,508.16 CNY [1][5]. Approval Process - The company has completed the necessary approval procedures for the incentive plan, including independent opinions from the board and verification from the supervisory board regarding the list of incentive objects [2][3]. Reasons for Repurchase - The repurchase is due to the departure of 9 individuals from the incentive plan and 1 individual being appointed as a supervisor, making them ineligible for the incentive [4][5]. - Additionally, the company needs to repurchase stocks corresponding to the second unlock period of the incentive plan due to unmet performance targets [5]. Impact on Share Structure - After the repurchase, the total share capital will decrease from 393,061,969 shares to 391,536,144 shares, with the proportion of restricted shares dropping from 0.88% to 0.50% [5]. - The repurchase will not significantly impact the company's financial status, operational results, or equity distribution, nor will it affect the management team's diligence or the continuation of the incentive plan [5].

证券代码：300685 证券简称：艾德生物 公告编号：2025-034 厦门艾德生物医药科技股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： ● 厦门艾德生物医药科技股份有限公司（以下简称"艾德生物"或"公司"）本次回购 注销限制性股票涉及379人，回购注销限制性股票1,525,825股，占回购注销前公司总股本 393,061,969股的0.388%； ● 限制性股票回购价格：对于当选为监事的激励对象，本次回购的首次授予限制性股票 回购价格为11.62元/股。除前述外，本次其他限制性股票回购价格均为11.62元/股加上银行同 期存款利息之和。本次回购价款合计为18,109,508.16元。 ● 截至本公告披露之日，公司在中国证券登记结算有限责任公司深圳分公司完成上述限 制性股票的回购注销手续。 一、本次激励计划已履行的相关审批程序 1、2023年9月8日，公司召开第三届董事会第十三次会议，会议审议通过了 《关于公司<2023年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2023年限 ...

Group 1 - The core viewpoint of the news is that Aide Biological's stock is underperforming compared to its industry peers, with a current PE ratio of 28.21, significantly lower than the industry average of 48.71 [1][2] - Aide Biological's market capitalization is reported at 7.932 billion yuan, ranking 65th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of 9.8921 million yuan in principal funds on May 22, with a total outflow of 8.7322 million yuan over the past five days [1] Group 2 - Aide Biological specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - For the first quarter of 2025, Aide Biological reported revenue of 272 million yuan, a year-on-year increase of 16.63%, and a net profit of 90.4718 million yuan, reflecting a year-on-year growth of 40.92% [1] - The company's gross profit margin stands at 83.48% [1]

Core Viewpoint - The company Aide Biology has initiated arbitration against Aivek for unpaid technology transfer fees amounting to 13.95 million yuan, following a previous agreement for a cancer early detection product [1][3][5]. Group 1: Arbitration Details - Aide Biology received an arbitration notice regarding a dispute over a technology transfer and licensing agreement with Aivek, with the claimed amount being 13.95 million yuan [1]. - The arbitration case involves a technology transfer fee that was previously recognized as a loss in the company's financial statements, indicating that it does not expect significant adverse effects on profits for the current and future years [1][5]. - The arbitration seeks to recover the unpaid technology transfer fee and associated penalties, totaling 13.35 million yuan in principal and 600,000 yuan in legal fees [5]. Group 2: Background of the Agreement - The technology transfer agreement was signed in June 2022, involving a cancer early detection product, the human SDC2 gene methylation detection kit, with a total transfer fee of 100 million yuan [3][4]. - Aide Biology initially received 50 million yuan as the first payment, with subsequent payments scheduled over four years, but Aivek has failed to make the second payment due in August 2024 [4][6]. - The product in question is significant as it was the first approved cancer early detection product by Aide Biology, enhancing its competitive position in the market [6][7]. Group 3: Strategic Rationale for the Transfer - Aide Biology's decision to transfer the asset was based on the differing commercialization models of cancer early detection products compared to its existing drug companion diagnostics, which made synergy with its sales team challenging [6][7]. - The company viewed the sale as an attempt to explore new commercial promotion models for cancer early detection products, acknowledging the need for substantial resources and the uncertainty of future returns [7].

1.案件所处的仲裁阶段：仲裁机构已受理，尚未开庭 2.公司所处的当事人地位：厦门艾德生物医药科技股份有限公司为仲裁申请人。 3.涉案的金额：暂计为13,955,000.00元 4.对公司损益产生的影响：公司依据《企业会计准则》及公司相关会计政策的规定，基 于谨慎性原则，对本案所涉技术转让价款在上一年度已充分计提了减值准备。预计本次仲裁 案件对公司本年度及以后年度利润不会产生重大不利影响。敬请投资者注意投资风险。 证券代码：300685 证券简称：艾德生物 公告编号：2025-033 厦门艾德生物医药科技股份有限公司 关于公司提起仲裁的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示: （一）仲裁各方当事人 一、本次仲裁事项受理的基本情况 近日，厦门艾德生物医药科技股份有限公司（以下简称"公司"或"申请人"） 收到中国国际经济贸易仲裁委员会上海分会发来的《SHDIP20250124号技术转让 及许可协议争议案仲裁通知》，中国国际经济贸易仲裁委员会上海分会收到申请 人公司以杭州艾维克生物科技有限公司（以下简称"被申请人"）为被申请人的 仲裁申请材 ...

Group 1 - The shareholder Xiamen Keying Investment Partnership has completed its reduction plan by selling 3.9252 million shares through block trading, which accounts for 1.00% of the total share capital [1] - After the reduction, Xiamen Keying's shareholding ratio has decreased to 4.06% [1]